BCL2 and cancer: Among the mechanisms of cancer chemoresistance development metabolic reprogramming, in particular, autophagy enhancement, activation of cancer stem cells, activation of anti-apoptotic signaling (MAPK, PI3K-AKT, Notch, Wnt signaling) [45,46,47], and production of anti-apoptotic proteins (i.e., Bcl-2) [48,49] are noted.